CLNN:NSD-Clene Inc (USD)

COMMON STOCK | | NSD

Last Closing Price

USD 12.58

Change

-0.26 (-2.02)%

Market Cap

USD 0.77B

Volume

0.03M

Average Target Price

USD 24.50 (+94.75%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is headquartered in Salt Lake City, Utah.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-09 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BOKFL BOK Financial Corporation

-0.02 (-0.08%)

USD5.27B 4.10 N/A
HCACW Hennessy Capital Acquisition C..

N/A

USD3.34B 11.29 N/A
TCBIL Texas Capital Bancshares, Inc

N/A

USD2.94B 22.81 N/A
DFH Dream Finders Homes, Inc

+0.45 (+1.92%)

USD2.20B N/A 27.92
OPINI Office Properties Income Trust

-0.01 (-0.04%)

USD1.28B 182.37 N/A
ARKO Arko Corp

-0.06 (-0.58%)

USD1.25B N/A 19.57
EOSE Eos Energy Enterprises, Inc

+0.41 (+2.45%)

USD0.88B N/A N/A
FTACW FinTech Acquisition Corp. III

N/A

USD0.63B 5.88 N/A
BTAQU Burgundy Technology Acquisitio..

-0.16 (-1.49%)

USD0.44B N/A N/A
GBLIZ Global Indemnity Limited

N/A

USD0.38B 3.94 N/A

ETFs Containing CLNN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification ()
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.77B N/A N/A 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
()
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2,269.33 N/A N/A 0% N/A
Price / Cash Flow Ratio -40.85 N/A N/A 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -456.75% N/A N/A 2% F
Return on Invested Capital 53.70% N/A N/A 98% A+
Return on Assets -30.40% N/A N/A 12% F
Debt to Equity Ratio 571.55% N/A N/A 2% F
Technical Ratios  
Short Ratio 1.43 N/A N/A 61% D-
Short Percent 0.27% N/A N/A 93% A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.